TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT04285268

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cause of deathSlow enrollment, also regulatory or ethics Automatic label, confidence 0.6, unverified. How labels are made.
“This study was never submitted to the IRB for review and approval. No research subjects were enrolled. .”

The sponsor’s own words in the registry.

Life of this trial

20202021202220232024202520262027Registered2020-02-24Planned start2020-05-06 (planned)Withdrawn (as of)2026-01-30

Vital statistics

Status
Withdrawn
Phase
Phase 2
Sponsor
Rutgers, The State University of New Jersey
Sponsor type
University, hospital or other
Conditions
High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
Interventions
Bortezomib; Rituximab; Venetoclax
Participants
0
Sites
1
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.